Kadcyla
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.kadcyla.comRevenue
$6.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Kadcyla
Learn about KADCYLA® a treatment for certain patients with HER2+ early breast cancer or HER2+ metastatic breast cancer. See Full Safety and Boxed Warnings for more information.Explore more
Popular SearchesKadcylaKADCYLA ®( adoSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kadcyla your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Kadcyla
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Kadcyla is spiking on competitors!
Website visits: Recent activity has been detected on your website
Kadcyla, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Kadcyla has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Kadcyla has new funding data
Click to see if Kadcyla had a recent Job posting/layoffs
Earning: See what the market has to say on Kadcyla recently announced quarterly report
Product Launch: Get notified when Kadcyla launches new products
Recommended Actions
Find VP level buyers at Kadcyla
Find 3 more new buyers
Compare Similar Companies to Kadcyla
Compare insights from companies similar to Kadcyla, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Kadcyla is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kadcyla is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kadcyla.
Kadcyla Tech Stack
A closer look at the technologies used by Kadcyla
See more technologies
Kadcyla News & Media
European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. “Optimal treatment iGenentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced completing the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for Kadcyla® (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) with residual disease after neoadjuvant (before surgery) treatment. The FDA is reviewing the application under tGenentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50 percent (HR=0.50, 95% CI 0.39-0.64, p<0.0001) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people withGenentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (EBC) who have residu
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kadcyla
Sign Up For FreeTo access detailed company insights
Learn about KADCYLA® a treatment for certain patients with HER2+ early breast cancer or HER2+ metastatic breast cancer. See Full Safety and Boxed Warnings for more information.... Read More
